AVITA MEDICAL INC (RCEL) Stock Overview
USA - NASDAQ:RCEL - US05380C1027 - Common Stock
RCEL Key Statistics, Chart & Performance
The current stock price of RCEL is 5.835 USD. In the past month the price increased by 19.82%. In the past year, price decreased by -46.32%.
RCEL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.85 | 390.07B | ||
| AMGN | AMGEN INC | 12.6 | 147.89B | ||
| GILD | GILEAD SCIENCES INC | 14.5 | 139.29B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.85 | 99.26B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.83 | 62.06B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.21B | ||
| ARGX | ARGENX SE - ADR | 79.22 | 44.94B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.8 | 39.49B | ||
| INSM | INSMED INC | N/A | 30.60B | ||
| NTRA | NATERA INC | N/A | 24.08B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.59B | ||
| BIIB | BIOGEN INC | 9.05 | 21.24B |
Related stock screener links
About RCEL
Company Profile
AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. The company is headquartered in Valencia California, California and currently employs 260 full-time employees. The company went IPO on 2012-03-18. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.
Company Info
AVITA MEDICAL INC
28159 Avenue Stanford, Suite 220
Valencia California CALIFORNIA 91355 US
CEO: Michael Perry
Employees: 260
Phone: 16613679170
AVITA MEDICAL INC / RCEL FAQ
What is the stock price of AVITA MEDICAL INC today?
The current stock price of RCEL is 5.835 USD. The price decreased by -6.64% in the last trading session.
What is the ticker symbol for AVITA MEDICAL INC stock?
The exchange symbol of AVITA MEDICAL INC is RCEL and it is listed on the Nasdaq exchange.
On which exchange is RCEL stock listed?
RCEL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AVITA MEDICAL INC stock?
13 analysts have analysed RCEL and the average price target is 8.98 USD. This implies a price increase of 53.83% is expected in the next year compared to the current price of 5.835. Check the AVITA MEDICAL INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AVITA MEDICAL INC worth?
AVITA MEDICAL INC (RCEL) has a market capitalization of 155.33M USD. This makes RCEL a Micro Cap stock.
How many employees does AVITA MEDICAL INC have?
AVITA MEDICAL INC (RCEL) currently has 260 employees.
What are the support and resistance levels for AVITA MEDICAL INC (RCEL) stock?
AVITA MEDICAL INC (RCEL) has a support level at 4.25 and a resistance level at 5.84. Check the full technical report for a detailed analysis of RCEL support and resistance levels.
Is AVITA MEDICAL INC (RCEL) expected to grow?
The Revenue of AVITA MEDICAL INC (RCEL) is expected to grow by 16.39% in the next year. Check the estimates tab for more information on the RCEL EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AVITA MEDICAL INC (RCEL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RCEL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RCEL, evaluating the profitability, health, valuation and growth aspects
- AVITA MEDICAL INC (RCEL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AVITA MEDICAL INC (RCEL) Sales and EPS estimates to see what analysts future expectations are.
- AVITA MEDICAL INC (RCEL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AVITA MEDICAL INC (RCEL) Insider and Institutional Ownership to learn about the owners and their transactions.
- AVITA MEDICAL INC (RCEL) Stock Chart to make your own analysis
- AVITA MEDICAL INC (RCEL) Latest news and press-releases to stay up to date.
Does AVITA MEDICAL INC (RCEL) stock pay dividends?
RCEL does not pay a dividend.
When does AVITA MEDICAL INC (RCEL) report earnings?
AVITA MEDICAL INC (RCEL) will report earnings on 2025-11-05, after the market close.
What is the Price/Earnings (PE) ratio of AVITA MEDICAL INC (RCEL)?
AVITA MEDICAL INC (RCEL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.97).
What is the Short Interest ratio of AVITA MEDICAL INC (RCEL) stock?
The outstanding short interest for AVITA MEDICAL INC (RCEL) is 17.43% of its float. Check the ownership tab for more information on the RCEL short interest.
RCEL Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to RCEL. When comparing the yearly performance of all stocks, RCEL is a bad performer in the overall market: 88.16% of all stocks are doing better.
RCEL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RCEL. RCEL has a bad profitability rating. Also its financial health evaluation is rather negative.
RCEL Financial Highlights
Over the last trailing twelve months RCEL reported a non-GAAP Earnings per Share(EPS) of -1.97. The EPS decreased by -1.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -88.71% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
RCEL Forecast & Estimates
13 analysts have analysed RCEL and the average price target is 8.98 USD. This implies a price increase of 53.83% is expected in the next year compared to the current price of 5.835.
For the next year, analysts expect an EPS growth of 65.99% and a revenue growth 16.39% for RCEL